Core Insights - Samsung Bioepis and Epis NexLab have signed a research collaboration and license agreement with G2GBIO to develop novel assets, including long-acting semaglutide, utilizing G2GBIO's proprietary microsphere technology [1][1][1] Group 1: Agreement Details - Samsung Bioepis will receive exclusive licensing rights for the long-acting semaglutide asset and an option to license another asset from G2GBIO [1][1] - The agreement includes first negotiation rights for three additional novel assets to be determined [1][1] - Epis NexLab will co-develop the long-acting microsphere drug delivery platform using G2GBIO's technology [1][1] Group 2: Company Background - Samsung Bioepis, established in 2012, is a biopharmaceutical company focused on making healthcare accessible through innovative product development [1][1] - The company aims to become a leading biopharmaceutical entity with a broad pipeline covering various therapeutic areas, including immunology, oncology, and endocrinology [1][1]

Company Overview - Samsung Bioepis Co., Ltd. has received marketing approval for Ustekinumab BS Subcutaneous Injection 45mg Syringes 'NIPRO', a biosimilar referencing Stelara, marking a significant milestone in its partnership with NIPRO CORPORATION established in June 2025 [1][2] - The company aims to provide accessible healthcare through innovations in product development and a commitment to quality, with a broad pipeline of biosimilar candidates across various therapeutic areas [4] Industry Context - Japan allocates approximately 10% of its GDP to healthcare, one of the highest rates among OECD countries, highlighting the increasing importance of biosimilars in reducing financial burdens on the healthcare system [2] - The approval of Ustekinumab BS is expected to expand access to high-quality, affordable treatment options for patients with autoimmune conditions, such as plaque psoriasis and psoriatic arthritis [2] Product Details - Ustekinumab is a human immunoglobulin G1 kappa (IgG1) monoclonal antibody that targets IL-12 and IL-23, which are associated with immune-mediated diseases [2] - The product is set to be included in Japan's National Health Insurance drug list in May 2026, allowing for immediate commercialization by NIPRO following the listing [2] Global Presence - Samsung Bioepis's Ustekinumab is already approved and available in multiple regions, including Australia, Brazil, Canada, Europe, Korea, Switzerland, the United Kingdom, and the United States [3]